In summary, we present the evidence that Il23r-/- mice are not protected from liver inflammation and fibrosis in two NASH preclinical models, thus suggesting that targeting IL-23 signaling alone may not be an effective therapeutic approach for NASH. The gene discussed is IL23A; the disease is metabolic dysfunction-associated steatohepatitis.